S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Abbott Laboratories Outlook is Healthy: Buy the Dip
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$6.33
-2.8%
$5.93
$5.26
$11.38
$260.76M0.66702,451 shs490,691 shs
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
Cerus Co. stock logo
CERS
Cerus
$1.64
-2.4%
$2.04
$1.21
$3.08
$304.55M1.291.24 million shs745,925 shs
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
$29.90
-0.9%
$28.12
$23.10
$53.50
$717.87M1.16172,827 shs279,703 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$5.25
+0.6%
$6.56
$4.38
$8.45
$399.38M0.15705,422 shs1.09 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-2.76%-7.59%+17.44%+8.39%-27.90%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
Cerus Co. stock logo
CERS
Cerus
-2.38%-3.81%-11.83%-2.96%-39.71%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-0.93%-5.89%+19.60%+5.47%-38.08%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
+0.57%-9.33%-22.79%-34.86%-21.29%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.7325 of 5 stars
3.54.00.04.23.53.31.3
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Cerus Co. stock logo
CERS
Cerus
2.6097 of 5 stars
3.33.00.00.03.12.50.6
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
4.0056 of 5 stars
3.41.00.03.92.54.20.6
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
4.0932 of 5 stars
2.25.00.04.22.41.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25125.12% Upside
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/A
Cerus Co. stock logo
CERS
Cerus
2.67
Moderate Buy$3.50113.41% Upside
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
2.75
Moderate Buy$42.5042.14% Upside
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.33
Hold$6.3821.43% Upside

Current Analyst Ratings

Latest ATRS, CERS, ANGO, KIDS, and OSUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Cerus Co. stock logo
CERS
Cerus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
4/10/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
4/4/2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$7.00 ➝ $6.50
3/7/2024
Cerus Co. stock logo
CERS
Cerus
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$2.50
3/7/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$50.00
3/6/2024
Cerus Co. stock logo
CERS
Cerus
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$3.00
1/25/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$39.00 ➝ $31.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$338.75M0.75$1.07 per share5.94$5.46 per share1.16
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
Cerus Co. stock logo
CERS
Cerus
$156.37M1.90N/AN/A$0.29 per share5.66
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
$148.73M4.78N/AN/A$16.14 per share1.85
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$405.47M0.99$1.35 per share3.89$5.86 per share0.90

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
Cerus Co. stock logo
CERS
Cerus
-$37.49M-$0.21N/AN/AN/A-23.98%-67.17%-17.68%5/2/2024 (Estimated)
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$20.97M-$0.92N/AN/AN/A-14.10%-5.03%-4.37%5/6/2024 (Estimated)
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$53.65M$0.727.29N/AN/A13.23%14.50%12.69%5/8/2024 (Estimated)

Latest ATRS, CERS, ANGO, KIDS, and OSUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/6/2024Q4 2023
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$0.28-$0.23+$0.05-$0.17$37.59 million$37.61 million
3/5/2024Q4 2023
Cerus Co. stock logo
CERS
Cerus
-$0.01-$0.01N/A-$0.01$46.80 million$46.77 million
2/27/2024Q4 2023
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$0.13$0.22+$0.09$0.17$74.13 million$75.88 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
Cerus Co. stock logo
CERS
Cerus
N/AN/AN/AN/AN/A
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
Cerus Co. stock logo
CERS
Cerus
1.12
2.14
1.55
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
0.03
5.44
2.90
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
9.77
8.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
Cerus Co. stock logo
CERS
Cerus
78.37%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
69.05%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%

Insider Ownership

CompanyInsider Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
Cerus Co. stock logo
CERS
Cerus
7.05%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
32.60%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
Cerus Co. stock logo
CERS
Cerus
625181.28 million168.50 millionOptionable
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
24723.79 million16.03 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
63876.51 million73.91 millionOptionable

ATRS, CERS, ANGO, KIDS, and OSUR Headlines

SourceHeadline
Files taken from Orasure systems in cybersecurity incidentFiles taken from Orasure systems in cybersecurity incident
medtechdive.com - April 17 at 5:08 PM
OraSure Technologies Experiences “Cybersecurity Incident” and Investigates Possible Data BreachOraSure Technologies Experiences “Cybersecurity Incident” and Investigates Possible Data Breach
jdsupra.com - April 17 at 2:07 AM
OraSure reports data breach, says impact containedOraSure reports data breach, says impact contained
investing.com - April 14 at 12:25 AM
OraSure Technologies Hit With Cybersecurity BreachOraSure Technologies Hit With Cybersecurity Breach
marketwatch.com - April 12 at 6:04 PM
OraSure reports cybersecurity breach, says incident has been containedOraSure reports cybersecurity breach, says incident has been contained
msn.com - April 12 at 6:04 PM
OraSure Technologies, Inc. (NASDAQ:OSUR) Short Interest UpdateOraSure Technologies, Inc. (NASDAQ:OSUR) Short Interest Update
marketbeat.com - April 12 at 4:32 PM
OraSure Technologies (NASDAQ:OSUR) & Carmell (NASDAQ:CTCX) Critical SurveyOraSure Technologies (NASDAQ:OSUR) & Carmell (NASDAQ:CTCX) Critical Survey
americanbankingnews.com - April 11 at 1:15 AM
OraSure Technologies (NASDAQ:OSUR) Price Target Lowered to $6.50 at Evercore ISIOraSure Technologies (NASDAQ:OSUR) Price Target Lowered to $6.50 at Evercore ISI
marketbeat.com - April 4 at 1:51 PM
Announcing speakers for the 2024 Builders Conference and Signature EventAnnouncing speakers for the 2024 Builders Conference and Signature Event
technical.ly - March 30 at 9:13 AM
OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc. (OSUR)
finance.yahoo.com - March 29 at 12:30 PM
Singapores DBS bank confident of 15%-17% ROE in next 3-5 years, CEO saysSingapore's DBS bank confident of 15%-17% ROE in next 3-5 years, CEO says
sg.finance.yahoo.com - March 28 at 9:28 PM
OraSure Technologies, Inc.s (NASDAQ:OSUR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?OraSure Technologies, Inc.'s (NASDAQ:OSUR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
finance.yahoo.com - March 28 at 11:23 AM
Pacer Advisors Inc. Increases Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)Pacer Advisors Inc. Increases Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)
marketbeat.com - March 27 at 6:12 AM
NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the BoardNOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board
finance.yahoo.com - March 21 at 9:26 AM
OSUR Oct 2024 10.000 callOSUR Oct 2024 10.000 call
finance.yahoo.com - March 16 at 7:56 AM
OSUR Jul 2024 5.000 putOSUR Jul 2024 5.000 put
finance.yahoo.com - March 16 at 7:56 AM
OraSure Technologies Full Year 2023 Earnings: EPS Beats ExpectationsOraSure Technologies Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 1 at 9:50 AM
OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Call TranscriptOraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 28 at 9:55 AM
Q4 2023 OraSure Technologies Inc Earnings CallQ4 2023 OraSure Technologies Inc Earnings Call
finance.yahoo.com - February 28 at 9:55 AM
OraSure Technologies: Q4 Earnings InsightsOraSure Technologies: Q4 Earnings Insights
benzinga.com - February 27 at 5:28 PM
OraSure Technologies Non-GAAP EPS of $0.22 beats by $0.11, revenue of $75.88M beats by $1.61MOraSure Technologies Non-GAAP EPS of $0.22 beats by $0.11, revenue of $75.88M beats by $1.61M
msn.com - February 27 at 5:28 PM
OraSure Technologies Inc (OSUR) Reports Q4 Revenue Decline Amidst Strategic Growth EffortsOraSure Technologies Inc (OSUR) Reports Q4 Revenue Decline Amidst Strategic Growth Efforts
finance.yahoo.com - February 27 at 5:28 PM
OraSure Reports Q4 ‘23 Revenue of $75.9 MillionOraSure Reports Q4 ‘23 Revenue of $75.9 Million
globenewswire.com - February 27 at 4:05 PM
OraSure to report fourth-quarter earnings, hold conference call Tuesday after close of marketsOraSure to report fourth-quarter earnings, hold conference call Tuesday after close of markets
wfmz.com - February 26 at 9:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Antares Pharma logo

Antares Pharma

NASDAQ:ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
Cerus logo

Cerus

NASDAQ:CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
OrthoPediatrics logo

OrthoPediatrics

NASDAQ:KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
OraSure Technologies logo

OraSure Technologies

NASDAQ:OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.